This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Carbohydrate Any compound containing carbon, hydrogen, sometimes oxygen. There is considerable variety in these compounds and only some of them are available to humans as a fuel source. Cellulose, for instance, is a carbohydrate, but humans and all non-cud chewing animals (except termites and some microorganisms) can make no use of it. Only a few of the simple sugars (mono-saccharides) and even fewer of the di-saccharides (e.g., lactose) in food are available to humans. Others, if they contribute to human nutrition, do so after processing by intestinal bacteria (some estimates are that, in humans, less than 10% of caloric benefit comes from fermentation in the large intestine, as contrasted to other primates in which the proportion is rather larger). Most carbohydrates that can be absorbed and used for fuel by humans (e.g., starch and glycogen—both chains of glucose molecules).are eventually broken down to glucose during digestion. They eventually are part of the primary metabolic control mechanism. Fructose, on the other hand, is a carbohydrate which is neither; it is absorbed, but in humans processed only in the liver and in sperm, the only tissues which have the required enzymes. Ingested carbohydrate calories in non glucose forms are, in a special sense, invisible to the body.
Palladium is a chemical element; it has the symbol Pd and atomic number 46. It is a rare and lustrous silvery-white metal discovered in 1802 by the English chemist William Hyde Wollaston. He named it after the asteroid Pallas (formally 2 Pallas), which was itself named after the epithet of the Greek goddess Athena, acquired by her when she slew Pallas. Palladium, platinum, rhodium, ruthenium, iridium and osmium form together a group of elements referred to as the platinum group metals. They have similar chemical properties, but palladium has the lowest melting point and is the least dense of them. More than half the supply of palladium and its congener platinum is used in catalytic converters, which convert as much as 90% of the harmful gases in automobile exhaust (hydrocarbons, carbon monoxide, and nitrogen dioxide) into nontoxic substances (nitrogen, carbon dioxide and water vapor). Palladium is also used in electronics, dentistry, medicine, hydrogen purification, chemical applications, electrochemical sensors, electrosynthesis, groundwater treatment, and jewelry. Ore deposits of palladium and other platinum group metals are rare. The most extensive deposits have been found in the norite belt of the Bushveld Igneous Complex covering the Transvaal Basin in South Africa; the Stillwater Complex in Montana, United States; the Sudbury Basin and Thunder Bay District of Ontario, Canada; and the Norilsk Complex in Russia. Recycling is also a source, mostly from scrapped catalytic converters.
An antibody–drug conjugate consists of three components: Antibody - targets the cancer cell surface and may also elicit a therapeutic response. Payload - elicits the desired therapeutic response. Linker - attaches the payload to the antibody and should be stable in circulation only releasing the payload at the desired target. Multiple approaches to conjugation have been developed for attachment to the antibody and reviewed. DAR is the drug to antibody ratio and indicates the level of loading of the payload on the ADC.
For many years, exobiologists have proposed the existence of a shadow biosphere, a postulated microbial biosphere of Earth that uses radically different biochemical and molecular processes than currently known life. One of the proposals was the existence of lifeforms that use arsenic instead of phosphorus in DNA. A report in 2010 of the possibility in the bacterium GFAJ-1 was announced, though the research was disputed, and evidence suggests the bacterium actively prevents the incorporation of arsenic into the DNA backbone and other biomolecules.
Sources: en.wikipedia.org
== Research == A synthetic antibody has been shown to neutralize a major class of neurotoxins produced by four deadly snake species from South Asia, Southeast Asia, and Africa. The antibody targets long-chain α-neurotoxins, a common and lethal component of many elapid venoms, and may represent a step toward a universal antivenom effective against a broad spectrum of snake species. Separately, a combination of broadly neutralizing human antibodies and the phospholipase inhibitor varespladib has been shown to protect mice from venom-induced lethality caused by multiple snake species. The antibodies were derived from a hyperimmune human donor who had developed broad resistance to snake venom through repeated exposures, resulting in a unique immune profile capable of neutralizing diverse venom toxins.
Morales even threatened to denounce Peru before the International Court of Justice in The Hague, because the Peruvian government granted diplomatic asylum to three former ministers of former President Sánchez de Losada, whom Morales described as "criminals", which he later It provoked anti-Peruvian marches in the city of El Alto by leftist movements and sindicalist, who threatened to expel all Peruvian citizens from the country and vandalize the Peruvian consulate if the former ministers' asylum is not revoked. On the other hand, Morales also accused Peru of wanting to "appropriate" the "cultural expressions" of Bolivia, to the point that the Bolivian Minister of Culture, Pablo Groux, threatened to take the dispute to the International Court of Justice in The Hague because they postulate that the diablada is native to Bolivia and not to Peru. In the following 5 years there were approximately ten complaints of appropriation of Bolivian folklore. The issue came to touch the national pride of both countries and fueled an anti-Peruvian position in several Bolivian nationalists opposed proposals to consider them bi-national. In addition, Evo went so far as to affirm that the demand of Peru in The Hague against Chile, due to the maritime delimitation controversy between the two countries, had the objective of blocking Bolivian aspirations for an outlet to the sea (through a corridor on the land border between Peru and Chile), stating that he had information in which the Peruvian Government "knows that the lawsuit is going to lose it.
The Theodor Bilharz Research Institute is located in Giza, Egypt. Theodor Bilharz was a German scientist who discovered, in autopsy material at Kasr El Aini Hospital, the causative agent of haematuria: Schistosoma worm, during his work in Egypt in 1851. The bilhariziasis disease was named after him.
AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about two per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about one per 1,000 deaths are from systemic amyloidosis. Amyloidosis has been described since at least 1639.
=== Brand names === Nalbuphine is marketed primarily under the brand names Nubain, Nalpain, and Nalbuphin. It is also marketed under the brand name Nalufin in Egypt and Nalbun in Bangladesh by Incepta Pharma Limited, under the brand name Rubuphine in India by Rusan Healthcare Pvt Ltd, under the brand name Kinz and Nalbin in Pakistan by Sami and Global Pharmaceuticals, under the brand name Analin by Medicaids in Pakistan, and under the brand name Exnal by Indus Pharma in Pakistan, among many others.
Sources: en.wikipedia.org
== Current Research and Future Implications == Currently, studies and experiments are being done to test for dedifferentiation-like abilities in mammalian cells, with hopes that this information can provide more insight into possible regenerative abilities in mammals. Dedifferentiation could spark innovation in regenerative medicine because it suggests that one's own cells can change cell fates, which would remove immunological response risks from treatment with allogeneic cells, or cells that are not genetically matched with the patient. A concept that has been explored for mammals is that of inducible dedifferentiation, which would make cells that do not naturally dedifferentiate be able to revert to a pluripotent or progenitor-like state. This is achieved by expressing the appropriate transcription factors in the cell and suppressing others. More information about this as well as the possible risks can be found here [1] .
Around 130,000 civil servants belonging to the PCS union vote to strike on 28 April in a dispute with the UK government over pay and conditions. HM Treasury scraps plans for the Royal Mint to produce a government-backed NFT that could be traded on international markets. 28 March Humza Yousaf is confirmed as Scotland's new First Minister by a vote in the Scottish Parliament. Former Labour leader Jeremy Corbyn is banned from standing as a candidate for the party at the 2024 general election after the party's National Executive Committee votes 22–12 in favour of a motion blocking his candidacy. 29 March Charles III begins a state visit to Germany, his first official overseas trip as monarch. The UK government introduces the Victims and Prisoners Bill into the House of Commons, which will give ministers the power to veto the release of some prisoners, and restrict marriage in prison for those serving whole life terms. Immigration Minister Robert Jenrick confirms the government's intention to utilise three locations, including two former military bases, to house migrants arriving into the UK as asylum seekers. The plans are an attempt by the government to save on hotel expenses. Humza Yousaf is sworn in as Scotland's First Minister at Edinburgh's Court of Session and begins naming his cabinet. 30 March The government publishes its latest net zero strategy for the period to 2050, following a High Court ruling that its earlier plans were insufficient to meet climate targets. High-profile inmate Charles Bronson loses his latest bid for freedom.
=== Protein detection with antibodies (immunoassays) === Antibodies to particular proteins, or their modified forms, have been used in biochemistry and cell biology studies. These are among the most common tools used by molecular biologists today. There are several specific techniques and protocols that use antibodies for protein detection. The enzyme-linked immunosorbent assay (ELISA) has been used for decades to detect and quantitatively measure proteins in samples. The western blot may be used for detection and quantification of individual proteins, where in an initial step, a complex protein mixture is separated using SDS-PAGE and then the protein of interest is identified using an antibody. Modified proteins may be studied by developing an antibody specific to that modification. For example, some antibodies only recognize certain proteins when they are tyrosine-phosphorylated, they are known as phospho-specific antibodies. Also, there are antibodies specific to other modifications. These may be used to determine the set of proteins that have undergone the modification of interest. Immunoassays can also be carried out using recombinantly generated immunoglobulin derivatives or synthetically designed protein scaffolds that are selected for high antigen specificity. Such binders include single domain antibody fragments (Nanobodies), designed ankyrin repeat proteins (DARPins) and aptamers. Disease detection at the molecular level is driving the emerging revolution of early diagnosis and treatment.
=== Project IMIS === Environmental radioactivity has been monitored in Germany since the 1950s. Until 1986, this was carried out by various authorities that did not coordinate with each other. Following the confusion during the Chernobyl reactor disaster in April 1986, measurement activities were pooled in the IMIS (Integrated Measurement and Information System) project, an environmental information system for monitoring radioactivity in Germany. Previously, the measuring equipment was affiliated to the warning offices under the name WADIS ("Warning service information system").
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.